Search

Crinetics Pharmaceuticals Inc

Avatud

SektorTervishoid

84.75 -0.02

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

84.4

Max

84.78

Põhinäitajad

By Trading Economics

Sissetulek

7M

-121M

Müük

14M

25M

Aktsiakasum

-1.14

Kasumimarginaal

-481.149

Töötajad

594

EBITDA

-4.7M

-131M

Soovitused

By TipRanks

Soovitused

Neutraalne

12 kuu keskmine prognoos

+0.99% upside

Dividendid

By Acuity

Järgmine tulemuste avaldamine

5. nov 2026

Turustatistika

By TradingEconomics

Turukapital

126M

9B

Eelmine avamishind

84.77

Eelmine sulgemishind

84.75

Uudiste sentiment

By Acuity

65%

35%

303 / 340 Pingereas Healthcare

Crinetics Pharmaceuticals Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

18. aug 2026, 23:56 UTC

News

Exelixis shares are lower in after-market hours following BMO's Market Perform rating. Broader market pressures from rising bond yields also weigh on the stock.

18. aug 2026, 23:56 UTC

News

Carvana Co's shares are higher in after-market trading amid concerns over major shareholder Mark Walter's federal investigation and potential stake sale valued at $2 billion.

18. aug 2026, 23:52 UTC

News
Social Media

IONQ partners with CMC Microsystems to enhance cloud quantum computing access in Canada. Shares are lower in after-market hours following the announcement.

18. aug 2026, 23:51 UTC

News
Social Media
Event

La-Z-Boy Inc reported a net loss of $2.29 million and lowered its revenue guidance, leading shares to trade lower in after-market hours.

18. aug 2026, 23:51 UTC

News

JBS N.V. has proposed to acquire an 18% stake in Pilgrim's Pride, offering 2.086 shares per Pilgrim's Pride share. Shares are higher in after-market trading.

18. aug 2026, 23:46 UTC

News

Blue Owl Capital shares are lower in after-market hours following a recent bond issuance of $400 million by its affiliate. Analysts estimate fair value at $12.38.

18. aug 2026, 23:41 UTC

News
Social Media

UGI Corp shares rose in after-market trading on news of KKR's unsolicited $9 billion acquisition proposal, valuing the company at about $42.50 per share.

18. aug 2026, 23:41 UTC

News

Halozyme shares are lower in after-market trading following the announcement of Dannielle Appelhans' election to the Board of Directors, effective August 2026.

18. aug 2026, 23:36 UTC

News

BMO Capital initiated coverage on Alnylam Pharmaceuticals with an Outperform rating and a price target of $318. Shares are higher in after-market trading.

18. aug 2026, 23:36 UTC

News
Correlated Moves

SPDR Gold Shares trade lower in after-market hours as Indonesia holds rates steady, while rising crude oil prices may affect inflation and market dynamics.

18. aug 2026, 23:21 UTC

News
Correlated Moves

Silver is trading lower in after-market hours, reflecting a decline alongside the United States Copper Index Fund. Silver remains above its 20-day moving average.

18. aug 2026, 23:21 UTC

Event
News

Jack Henry & Associates projects fiscal 2027 GAAP sales of $2.684 billion to $2.709 billion, exceeding analyst estimates, as shares rise in after-market hours.

18. aug 2026, 23:21 UTC

News

Evolution Petroleum shares are lower in after-market trading following a public offering announcement to fund a $16 million acquisition in the Midland Basin.

18. aug 2026, 23:21 UTC

News

Norfolk Southern completed its Living Shoreline project and advanced in after-market trading, showing strength above its 20-day moving average.

18. aug 2026, 23:21 UTC

News

Enovix Corporation shares rise in after-market hours as executives reassure investors and reaffirm Q3 2026 revenue guidance of $9.0 million to $10.0 million.

18. aug 2026, 23:11 UTC

Correlated Moves
News

Photronics Inc is facing a potential securities fraud lawsuit, contributing to a decline in after-market trading. The Russell 2000 Index also showed a slight decrease.

18. aug 2026, 23:06 UTC

News
Social Media

Eli Lilly shares are lower in after-market hours amid scrutiny over its planned acquisition of Sangamo's gene therapy technologies from Genentech and others.

18. aug 2026, 23:02 UTC

News
Correlated Moves
Social Media

Price target raised to $1,250; shares lower in after-market.

18. aug 2026, 23:01 UTC

News

Toll Brothers reported third-quarter earnings of $280.1 million, exceeding expectations. Shares are trading higher in after-market hours following the results.

18. aug 2026, 23:01 UTC

News

Automatic Data Processing shares are lower in after-market trading despite a rebound in U.S. private-sector hiring, amid rising U.S. Treasury yields.

18. aug 2026, 23:01 UTC

News
Social Media

Mercury Systems shares fell after reporting a decline in net income to $798,000 and missing adjusted EPS estimates by $0.02 in after-market trading.

18. aug 2026, 23:01 UTC

News

Union Pacific shares are higher in after-hours trading as the Surface Transportation Board advances merger discussions with Norfolk Southern, boosting investor sentiment.

18. aug 2026, 23:01 UTC

News
ETF Constituents

The Vanguard Growth ETF is higher in after-market trading, supported by gains in META and AMZN, despite broader market pressures from inflation and geopolitical tensions.

18. aug 2026, 23:01 UTC

News
Social Media
Event

Keysight Technologies reported third-quarter revenue of $1.846 billion, exceeding expectations. Shares rose in after-market trading following the strong earnings and raised guidance.

18. aug 2026, 23:01 UTC

News

Blue Owl Capital shares are higher in after-market hours as Blue Owl Technology Finance prices $400 million in bonds, exceeding its $200 million target.

18. aug 2026, 23:01 UTC

News
Social Media

Dell Technologies shares are lower in after-market trading amid broader market pressures and rising U.S. Treasury yields ahead of its September 1 earnings call.

18. aug 2026, 23:01 UTC

News

Kennametal Inc appointed Dawne S. Hickton and Richard J. Harshman to its Board of Directors, prompting shares to advance in after-market trading.

18. aug 2026, 22:02 UTC

News

Curtiss-Wright Corp announced a $100 million expansion of its share repurchase program, raising total buybacks to $260 million for 2026. Shares are higher in after-market trading.

18. aug 2026, 21:03 UTC

News

Geron Corporation's shares are lower in after-market trading following the grant of stock options to new employees at an exercise price of $1.53.

18. aug 2026, 21:01 UTC

News

Cinemark Holdings Inc. shares rise after *Spider-Man: Brand New Day* becomes the highest-grossing domestic film in the company's history within three weeks of release.

Võrdlus sarnastega

Hinnamuutus

Crinetics Pharmaceuticals Inc Prognoos

Hinnasiht

By TipRanks

0.99% tõus

12 kuu keskmine prognoos

Keskmine 85.56 USD  0.99%

Kõrge 95 USD

Madal 80 USD

Põhineb 14 Wall Streeti analüütiku instrumendi Crinetics Pharmaceuticals Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Neutraalne

14 ratings

2

Osta

12

Hoia

0

Müü

Sentiment

By Acuity

303 / 340 Pingereas Tervishoid

Uudiste sentiment

Tõusu märgid

Volatiilsus

Alla keskmise

Uudismaht (RCV)

Alla keskmise

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest Crinetics Pharmaceuticals Inc

Crinetics Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company's lead product candidate is paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist, which is in Phase 3 trial for the treatment of acromegaly; and Phase 2 trial for treating carcinoid syndrome associated with neuroendocrine tumors. It is also developing CRN04894, an investigational oral nonpeptide product candidate to antagonize the adrenocorticotrophic hormone (ACTH) receptor that has completed a Phase 1 study for the treatment of diseases caused by excess ACTH, including congenital adrenal hyperplasia and Cushing's disease. In addition, the company is developing antagonists of the parathyroid hormone (PTH) receptor for the treatment of primary hyperparathyroidism and humoral hypercalcemia of malignancy, and other diseases of excess PTH; identified investigational orally available somatostatin receptor type 3 targeted nonpeptide agonists for the treatment of autosomal dominant polycystic kidney disease; and developing thyroid-stimulating hormone receptor antagonists for the treatment of graves' disease and thyroid eye disease, as well as Oral GLP-1 and GIP nonpeptides for the treatment of diabetes and obesity. Crinetics Pharmaceuticals, Inc. was incorporated in 2008 and is headquartered in San Diego, California.
help-icon Live chat